US 12,188,925 B2
Multi-stage, multiplexed target isolation and processing from heterogeneous populations
Paul Blainey, Cambridge, MA (US); Dwayne Vickers, San Diego, CA (US); and Nir Hacohen, Brookline, MA (US)
Assigned to The Broad Institute, Inc., Cambridge, MA (US); The General Hospital Corporation, Boston, MA (US); and Massachusetts Institute of Technology, Cambridge, MA (US)
Filed by THE BROAD INSTITUTE, INC., Cambridge, MA (US); MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA (US); and THE GENERAL HOSPITAL CORPORATION, Boston, MA (US)
Filed on Jan. 29, 2021, as Appl. No. 17/163,054.
Application 17/163,054 is a division of application No. 16/075,258, granted, now 10,962,527, previously published as PCT/US2017/016546, filed on Feb. 3, 2017.
Claims priority of provisional application 62/292,074, filed on Feb. 5, 2016.
Prior Publication US 2022/0034869 A1, Feb. 3, 2022
Int. Cl. B01L 3/00 (2006.01); B01F 23/00 (2022.01); B01F 23/41 (2022.01); B01F 101/23 (2022.01); B23Q 17/24 (2006.01); B81B 7/02 (2006.01); B81C 1/00 (2006.01); B81C 3/00 (2006.01); C07K 14/705 (2006.01); C12M 1/34 (2006.01); C12Q 1/04 (2006.01); C12Q 1/18 (2006.01); C12Q 1/686 (2018.01); G01N 21/3577 (2014.01); G01N 21/359 (2014.01); G01N 21/39 (2006.01); G01N 21/45 (2006.01); G01N 21/64 (2006.01); G01N 27/414 (2006.01); G01N 30/12 (2006.01); G01N 30/68 (2006.01); G01N 30/70 (2006.01); G01N 30/72 (2006.01); G01N 30/88 (2006.01); G01N 33/00 (2006.01); G01N 33/18 (2006.01); G01N 33/50 (2006.01); G01N 33/53 (2006.01); G01N 33/536 (2006.01); G01N 33/543 (2006.01); G01N 33/58 (2006.01); G01N 33/68 (2006.01); G01N 33/74 (2006.01); G02F 1/1335 (2006.01); H10K 10/46 (2023.01); H10K 85/00 (2023.01); H10K 85/20 (2023.01)
CPC G01N 33/5044 (2013.01) [B01L 3/502715 (2013.01); B01L 3/502761 (2013.01); G01N 33/536 (2013.01); G01N 33/543 (2013.01); G01N 33/54326 (2013.01); G01N 33/58 (2013.01); B01L 2300/0861 (2013.01); G01N 33/587 (2013.01)] 11 Claims
OG exemplary drawing
 
1. A cell isolation platform, comprising:
a microfluidic chip, comprising a plurality of processing units, each processing unit comprising: an inlet port, a plurality of first chambers connected to the inlet port by a first fluid channel, the first fluid channel comprising a plurality of valves, a plurality of second chambers, each of the second chambers connected to a respective first chamber by a second fluid channel, each second fluid channel including a controllable blocking valve, and a plurality of respective outlet ports, each outlet port in fluid communication with a respective one of said second chambers and each outlet port including a blocking valve;
a magnet adjacent the microfluidic chip, wherein relative positioning of the magnet and the microfluidic chip is variable and wherein movement of the magnet results in the movement of magnetic beads configured to bind a cell-specific marker to contact cells having the cell-specific marker within the microfluidic chip; and
a valve control configured to actuate certain ones of the controllable blocking valves in response to a control signal.